Ceribell, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ceribell, Inc. (CBLL) on June 12, 2025. The filing reports the entry into a material definitive agreement regarding the extension of an exclusive intellectual property license.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial figure disclosed is the $250,000 option exercise fee paid to Stanford University to extend the license agreement.
Material Changes
The primary material change is the execution of Amendment No. 4 to the Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University. Under this amendment, Ceribell exercised an option to extend the exclusivity of its license for portable brain wave activity devices through the expiration of the last-to-expire licensed patent. This action replaced a previously scheduled $20,000 payment due in April 2025, which was waived upon the payment of the $250,000 exercise fee.
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation of the agreement execution. The filing notes that the description of the amendment is qualified by reference to the full text of Exhibit 10.1. No specific guidance, forward-looking financial projections, or new risk factors are disclosed in this report.
Investor Verification Checklist
- Verify the total remaining term of the extended patent exclusivity.
- Confirm the impact of the $250,000 payment on the company's current cash position.
- Review the full text of Amendment No. 4 (Exhibit 10.1) for any additional covenants or obligations.
- Assess the strategic importance of the extended license to the company's core product pipeline.